Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer

Gastric Cancer

Volumn 19, Issue 1, 2016, Pages 234-244

  Wang, Jinwan ^a   Xu, Ruihua ^b   Li, Jian ^c   Bai, Yuxian ^d   Liu, Tianshu ^e   Jiao, Shunchang ^f   Dai, Guanghai ^f   Xu, Jianming ^g   Liu, Yunpeng ^h   Fan, Nanfeng ⁱ   Shu, Yongqian ^j   Ba, Yi ^k   Ma, Dong ^l   Qin, Shukui ^m   Zheng, Leizhen ⁿ   Chen, Weichang ^o   Shen, Lin ^c  

^a CANCER HOSPITAL   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^d HARBIN MEDICAL UNIVERSITY   (China)

^e ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^f CHINESE PLA GENERAL HOSPITAL   (China)

^g Beijing 307 Hospital   (China)

^h CHINA MEDICAL UNIVERSITY   (China)

ⁱ Fujian Provincial Maternity Hospital   (China)

^j Jiangsu Provincial Hospital   (China)

^k TIANJIN MEDICAL UNIVERSITY   (China)

^l GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^m PLA Cancer Center of Bayi Hospital   (China)

ⁿ XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^o THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

more..

Author keywords

Advanced gastric cancer; Modified docetaxel and cisplatin plus fluorouracil regimen; Overall survival; Progression free survival; Safety

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHINA; CHINESE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GASTROESOPHAGEAL JUNCTION CANCER; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL RESPONSE RATE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TIME TO TREATMENT FAILURE; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; PATHOLOGY; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84951568174     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-015-0457-4     Document Type: Article

References (28)

1. Shen L, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, et al. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14:e535–47.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.
3. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993;72:37–41.
4. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71:587–91.
5. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7.
6. Allum WH, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, Wong R, et al. Guidelines for the management of oesophageal and gastric cancer. Gut. 2011;60:1449–72.
7. Chen XL, Chen XZ, Yang C, Liao YB, Li H, Wang L, et al. Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis. PLoS One. 2013;8:e60320.
8. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007;25:3205–9.
9. Tomasello G, Chiesa MD, Buti S, Brighenti M, Negri F, Rovere RK, et al. Dose-dense chemotherapy in metastatik gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen. Tumori. 2010;96:48–53.
10. Ben Aharon I, Purim O, Kundel Y, Brenner R, Gordon N, Sulkes A. The combination of docetaxel, cisplatin, and 5-fluorouracil in advanced gastric cancer: a single-institution experience. Anticancer Drugs. 2012;23:313–20.
11. Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, et al. Split-dose docetaxel, cisplatin and leucovorin/luorouracil as first line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol. 2007;18:1673–9.
12. Park SR, Chun JH, Kim YW, Lee JH, Choi IJ, Kim CG, et al. Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma. Am J Clin Oncol. 2005;28:433–8.
13. Chi YHBL, Ren JH, Yang L, Cui CX, Li JL, Wang JW. Phase II clinical study on the modified DCF regimen for treatment of advanced gastric carcinoma. Chin Med J. 2011;124:2997–3002.
14. Inal A, Kaplan MA, Kucukoner M, Isikdogan A. Docetaxel and cisplatin plus fluorouracil compared with modified docetaxel, cisplatin, and 5-fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution. Neoplasma. 2012;59:233–6.
15. Ozdemir NY, Abali H, Oksuzoglu B, Budakoglu B, Uncu D, Guler T, et al. The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. Med Oncol. 2010;27:680–4.
16. Kang SH, Kim JI, Goh PG, Hwang SW, Kwon DS, Nam KW, et al. Docetaxel-cisplatin-5-FU combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric cancer. Korean J Gastroenterol. 2007;50:157–63.
17. Tebbutt NC, Cummins MM, Sourjina T, Strickland A, Van Hazel G, Ganju V, et al. Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer. 2010;102:475–81.
18. Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, et al. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer (Phila). 2010;116:1446–53.
19. Keskin S, Yıldız I, Sen F, Aydogan F, Kilic L, Ekenel M, et al. Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC). Clin Transl Oncol. 2013;15:403–8.
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.
21. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed 7 Oct 2014.
22. ®) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer. 1994;70:380–3.
23. Einzig AI, Neuberg D, Remick SC, Karp DD, O’Dwyer PJ, Stewart JA, et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol. 1996;13:87–93.
24. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.
25. Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, et al. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol. 2014;140:319–28.
26. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063–9.
27. Lordick F, Siewert JR. Perioperative Chemotherapie vs. alleinige Chirurgie bei resektablen gastroösophagealen Karzinomen. Chirurg. 2006;77:1166–7.
28. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry. Clinical trial endpoints for the approval of cancer drugs and biologics. 2007. http://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf. Accessed 8 Dec 2014.